tm logo
LYBALVI
Live/Registered
REGISTERED

on 20 Jul 2021

Last Applicant/ Owned by

1 Burlington Road

Dublin

IE

Serial Number

87700839 filed on 29th Nov 2017

Registration Number

6428572 registered on 20th Jul 2021

in the Principal Register

Correspondent Address

Norm J. Rich

FOLEY & LARDNER LLP

3000 K STREET, N.W.

SIXTH FLOOR

WASHINGTON, DC 20007

Filing Basis

1. intent to use

2. use application currently

Disclaimer

NO DATA

LYBALVI

Pharmaceutical preparations for the treatment of psychiatric and neurodegenerative diseases and disorders including schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, bipolar disorder; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidemia

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for the treatment of psychiatric and neurodegenerative diseases and disorders including schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, bipolar disorder; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidemia


First Use Date in General

19th Apr 2021

First Use Date in Commerce

19th Apr 2021

Mark Details


Serial Number

No 87700839

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 029318-2784

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
20th Jul 2021REGISTERED-PRINCIPAL REGISTER
17th Jun 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
16th Jun 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
17th May 2021SU - NON-FINAL ACTION - WRITTEN
17th May 2021NON-FINAL ACTION E-MAILED
17th May 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
26th Apr 2021STATEMENT OF USE PROCESSING COMPLETE
22nd Apr 2021USE AMENDMENT FILED
22nd Apr 2021TEAS STATEMENT OF USE RECEIVED
10th Nov 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED